

Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia

NCT07247279

Status RECRUITING
Sponsor AstraZeneca
Enrollment 450 participants

Key Eligibility Criteria

Inclusion (2)

- Adults (≥18 years) diagnosed with generalized MG positive for acetylcholine receptor (AChR) antibodies.
- Provision of signed and dated written informed consent.

Exclusion (2)

- Participants currently enrolled in clinical studies for treatment of gMG.
- Ocular MG only.

Locations (3 total)

Research Site, Kazan', Russia
Research Site, Novosibirsk, Russia
Research Site, Rostov-on-Don, Russia